Samuel Vaughn

Samuel Vaughn


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
SVSamuel Vaughn
Samuel Vaughn
JSJeffrey R. Strawn
Jeffrey R. Strawn
EPEthan Poweleit
Ethan Poweleit
MSMayur Sarangdhar
Mayur Sarangdhar
Laura B. RamseyLaura B. Ramsey
Laura B. Ramsey
The neuropharmacology of marijuana, including its effects on selective serotonin reuptake inhibitor (SSRI)/antidepressant metabolism and the subsequent response and tolerability in youth, has received limited attention. We sought to (1) review clinically relevant pharmacokinetic (PK) and pharmacodynamic (PD) interactions between cannabinoids and selected SSRIs, (2) use PK models to examine the impact of cannabinoids on SSRI exposure (area under curve (AUC)) and maximum concentration (CMAX) in adolescents, and (3) examine the frequency of adverse events reported when SSRIs and cannabinoids are used concomitantly. Cannabinoid metabolism, interactions with SSRIs, impact on relevant PK/PD pathways and known drug–drug interactions were reviewed. Then, the impact of tetrahydrocannabinol (THC) and cannabidiol (CBD) on exposure (AUC24) and CMAX for escitalopram and sertraline was modeled using pediatric PK data. Using data from the Food and Drug Administration Adverse Events Reporting System (FAERS), the relationship between CBD and CYP2C19-metabolized SSRIs and side effects was examined. Cannabis and CBD inhibit cytochrome activity, alter serotonergic transmission, and modulate SSRI response. In PK models, CBD and/or THC increases sertraline and es/citalopram concentrations in adolescents, and coadministration of CBD and CYP2C19-metabolized SSRIs increases the risk of cough, diarrhea, dizziness, and fatigue. Given the significant SSRI–cannabinoid interactions, clinicians should discuss THC and CBD use in youth prescribed SSRIs and be aware of the impact of initiating, stopping, or decreasing cannabinoid use as this may significantly affect es/citalopram and sertraline exposure.

12 October 2022 in Journal of the American Academy of Child & Adolescent Psychiatry
Verified
Journal Article
Closed access
PDF file
SVSamuel Vaughn
Samuel Vaughn
AKAmi Kanu
Ami Kanu
MJMichelle Johnston
Michelle Johnston
EPEthan A. Poweleit
Ethan A. Poweleit
JSJeffrey Robert Strawn
Jeffrey Robert Strawn
LRLaura B. Ramsey
Laura B. Ramsey